- Home
- SGRP vs NXL Comparison
SGRP vs NXL Comparison
Compare SGRP & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRP
- NXL
- Stock Information
- Founded
- SGRP 1967
- NXL 2010
- Country
- SGRP United States
- NXL United States
- Employees
- SGRP N/A
- NXL N/A
- Industry
- SGRP Business Services
- NXL Medical Specialities
- Sector
- SGRP Consumer Discretionary
- NXL Health Care
- Exchange
- SGRP Nasdaq
- NXL Nasdaq
- Market Cap
- SGRP 27.8M
- NXL 24.2M
- IPO Year
- SGRP 1996
- NXL 2022
- Fundamental
- Price
- SGRP $1.04
- NXL $1.23
- Analyst Decision
- SGRP
- NXL Strong Buy
- Analyst Count
- SGRP 0
- NXL 1
- Target Price
- SGRP N/A
- NXL $5.00
- AVG Volume (30 Days)
- SGRP 43.2K
- NXL 111.7K
- Earning Date
- SGRP 05-27-2025
- NXL 05-13-2025
- Dividend Yield
- SGRP N/A
- NXL N/A
- EPS Growth
- SGRP N/A
- NXL N/A
- EPS
- SGRP 0.50
- NXL N/A
- Revenue
- SGRP $228,869,000.00
- NXL $131,065.00
- Revenue This Year
- SGRP N/A
- NXL $79.59
- Revenue Next Year
- SGRP N/A
- NXL $334.65
- P/E Ratio
- SGRP $2.14
- NXL N/A
- Revenue Growth
- SGRP N/A
- NXL N/A
- 52 Week Low
- SGRP $1.00
- NXL $0.53
- 52 Week High
- SGRP $3.12
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- SGRP 34.96
- NXL 27.77
- Support Level
- SGRP $1.00
- NXL $1.15
- Resistance Level
- SGRP $1.08
- NXL $1.33
- Average True Range (ATR)
- SGRP 0.05
- NXL 0.13
- MACD
- SGRP 0.01
- NXL -0.03
- Stochastic Oscillator
- SGRP 26.67
- NXL 9.04
About SGRP SPAR Group Inc.
SPAR Group Inc is a supplier of merchandising and other marketing services. It also provides range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from Americas.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.